Aurinia

Aurinia Pharmaceuticals: Potential For Significant Upside By Year-End 2024 (NASDAQ:AUPH)

admin4 weeks ago034 mins

Editor’s note: Seeking Alpha is proud to welcome Pivotal Biotech as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Premium access. Click here to find out more » Hiroshi Watanabe Summary On…

Aurinia Pharmaceuticals: Sales Growth Would Help Buyout Potential (NASDAQ:AUPH)

admin4 months ago010 mins

Aksana Kavaleuskaya/iStock via Getty Images Aurinia Pharmaceuticals (NASDAQ:AUPH) markets Lupkynis (voclosporin) which was approved in January 2021 by the US Food and Drug Administration for the treatment of lupus nephritis. A recent preliminary update on Q4’23 and full-year 2023 financials provides an opportunity to look at where the company stands now. Is it finally time…

Zurich Insurance Group AG (ZURVY) Q1 2024 Earnings Call Transcript

Imperial Petroleum: New Recovery Highs Following Strong Q1 Performance – Buy (NASDAQ:IMPP)

Milestone Scientific Inc. (MLSS) Q1 2024 Earnings Call Transcript

Advanced Drainage Systems, Inc. (WMS) Q4 2024 Earnings Call Transcript

DXC Technology Company (DXC) Q4 2024 Earnings Call Transcript

Nvidia Earnings: Bulls Have Fingers On The Trigger (Technical Analysis) (NASDAQ:NVDA)

Aurinia Pharmaceuticals: Potential For Significant Upside By Year-End 2024 (NASDAQ:AUPH)

Aurinia Pharmaceuticals: Sales Growth Would Help Buyout Potential (NASDAQ:AUPH)